Download
Download by
Scanning QR Code
Download app
Download app

港股异动 | 四环医药(00460)再升5% 吡罗西尼新III期临床获批,超10款新药正进行临床试验

智通财经 ·  {{timeTz}}

智通财经APP获悉,四环医药(00460)继续放量上行,盘初股价逆市升约5%。截至发稿,四环医药涨4.88%,报1.72港元,成交额1.29亿港元。

四环医药(00460.HK)11月25日午间宣布,集团旗下轩竹生物在研1类创新药吡罗西尼(Birociclib,XZP-3287CDK4/6(细胞周期依赖性激酶4和6)抑制剂)(“吡罗西尼”)开展三期临床试验的申请已经获得正式批准。具体为:吡罗西尼与芳香化酶抑制剂联合用于激素受体阳性(HR+)、人表皮生长因子受体2阴性(HER2-)的局部晚期或转移性乳腺癌。此外,今年8月,吡罗西尼与氟维司群的联合治疗同样获批开展三期临床试验。

四环医药介绍称,目前轩竹生物合计拥有超过25个在研新药,超过10款新药处于临床不同阶段。

This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top